Drug intelligence / Profile preview

VVN481

Development stage: Unknown
Lead developer: VivaVision Biotech
Modality: Small Molecules
Administration: Ophthalmic

Overview

VVN481 is a small molecule drug under development by VivaVision Biotech for the treatment of eye diseases. It is currently in the discovery phase, with its primary therapeutic area being ocular conditions. Specific details about its mechanism of action, molecular targets, or chemical structure have not been disclosed publicly as of June 2025. The drug has received funding and is part of VivaVision's pipeline focused on innovative therapies for anterior and posterior segment eye diseases[1][3].

Targets

JAK1 (Janus kinase 1)TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on VVN481.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VVN481.

Explore the full profile